BioCentury
ARTICLE | Strategy

R&D reboot

Review: Biogen Idec pipeline after program cuts; where holes need to be filled

August 29, 2011 7:00 AM UTC

Charged with a mandate to reinvigorate and streamline R&D and ensure investors see value for money spent, Biogen Idec Inc.'s new management has pruned the pipeline and instilled a new culture of intelligent risk taking.

CEO George Scangos took the first step shortly after taking over in June 2010 with a restructuring that refocused the company on neurology and immunology while exiting cancer and cardiovascular indications...